Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
Status:
Not yet recruiting
Trial end date:
2029-09-01
Target enrollment:
Participant gender:
Summary
This research is being done to assess the effectiveness and safety of acalabrutinib combined
with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive
B-cell lymphoma.
This research study involves the study drug acalabrutinib in combination with lisocabtagene
maraleuce